Humanetics Corporation

Humanetics Corporation is a privately held, clinical stage pharmaceutical company based in the Minneapolis metropolitan area. The company employs 8 people and generates revenue exceeding $10,000. Humanetics develops BIO 300, a pharmaceutical candidate with multiple applications. This lead drug aims to improve the effectiveness of radiation treatment for solid tumor cancers while minimizing side effects like radiation pneumonitis, erectile dysfunction, mucositis, and xerostomia. BIO 300 is also being researched for its potential in treating inflammatory lung diseases, particularly in mitigating pulmonary injury resulting from COVID-19. The company secured a contract from the National Institute of Allergy and Infectious Diseases (NIAID) to fund a phase 2 study investigating BIO 300's effectiveness in recovering COVID-19 patients and preventing long-term lung complications such as fibrosis. BIO 300 was initially developed by the US Department of Defense for preventing ionizing radiation injuries, a program that continues today. For more details about Humanetics Corporation, please visit their website at www.humaneticscorp.com.